2014-003100-78: A clinical trial to test if the drug SMT C1100 is safe and well absorbed compared to placebo when given to children with Duchenne Muscular Dystrophy (DMD), who follow a balanced diet. |
|
|
| Ongoing | 1 | 12 | Europe | SMT C1100, Oral suspension | Summit (Oxford) Limited, Summit (Oxford) Limited | Duchenne Muscular Dystrophy, An inherited disease causing muscle degeneration., Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | | | | |
2015-001967-38: A research project for boys with Duchenne muscular dystrophy aged 5-9 years. It aims to find out how safe and well tolerated different doses of the experimental medicine are, when given by mouth after breakfast and evening meal. |
|
|
| Ongoing | 1 | 24 | Europe | SMT C1100 (F5; nanosuspension), SMT C1100 (F6; Powder for Oral Suspension), SMT C1100 (F5), SMT C1100 (F6), Oral suspension, Powder for oral suspension | Summit (Oxford) Limited | Duchenne muscular dystrophy (DMD), A progressive, lethal muscle wasting disease, characterised by a generalised weakness and progressive loss of muscle strength; cardiac and respiratory difficulties present, leading to death, Diseases [C] - Musculoskeletal Diseases [C05] | | | | |
